Relugolix combination therapy for treating endometriosis-associated pain
Relugolix in combination with estradiol and norethindrone is currently in clinical development for the treatment of endometriosis-associated pain. Endometriosis is a common, long-term gynaecological disorder where the tissue that normally lines the womb (endometrium) grows in other places. When this tissue breaks down as part of the normal menstrual cycle it becomes trapped in a …
Liposomal bupivacaine for post-operative pain in children
Liposomal bupivacaine is in clinical development for the treatment of post-operative pain in paediatric patients. Post-operative pain is a common occurrence in patients who have undergone surgery. Managing post-operative pain is important in order for patients to have a positive post-operative experience and to enhance their recovery, and for the prevention of chronic post-surgical pain in the long-term.
Liposomal bupivacaine for post-operative pain
Liposomal bupivacaine is in late-stage clinical development for the treatment of postoperative pain in adults. Post-operative pain is a common occurrence for those patients who have surgery. Controlling post-operative pain is important for ensuring a good patient experience, optimising post-operative outcomes and enhancing recovering, and the prevention of chronic postsurgical pain in the longer term.
Remimazolam for general anaesthesia – first line
Remimazolam is an intravenous anaesthetic which is similar to the commonly used sleep-inducing drug midazolam, but it incorporates properties to make the offset of sedation faster and more predictable. If licensed, remimazolam will offer an additional first-line intravenous general anaesthetic treatment for induction and maintenance of general anaesthesia in adults.
Bupivacaine and meloxicam (HTX-011) for post-operative pain
Bupivacaine and meloxicam (HTX-011) in a fixed-dose combination is in development for the management of post-operative pain. Post-operative pain is a typical example of acute pain. Acute pain typically lasts for less than 3-6 months (unlike chronic pain which carries on for longer than 12 weeks), and is provoked by identifiable stimuli and disappears as soon as the tissue injury or damage that had caused it is healed. All surgical procedures are associated with a certain level of post-operative pain. Opioids are often used to manage post-operative pain but carry the risk of harmful side effects, abuse and addiction.
Tanezumab for moderate to severe chronic pain associated with osteoarthritis and chronic low back pain
Tanezumab is in clinical development for the treatment of moderate to severe chronic pain associated with osteoarthritis and chronic low back pain. Pain is an unpleasant sensory experience associated with damage to body tissues due to an injury, physical pressure, or inflammation of some part of the body. Chronic pain is persistent or recurrent and lasts for longer than 12 weeks. Moderate pain interferes significantly with daily living activities, and severe pain is disabling and causes an inability to perform daily living activities. Effective long-term treatment options for managing moderate to severe chronic pain are limited. Currently available pain medicines like opioids and analgesics may increase the risks of addiction, gastrointestinal, cardiovascular and renal problems.
Rimegepant for the treatment of Acute Migraine
Rimegepant potentially offers an alternative to current agents, particularly for patients who have contraindications to the use of triptans. This includes patients with underlying cardiovascular diseases, or who either do not respond or have inadequate or inconsistent response to triptans or are intolerant to them.
Neridronic Acid (Nerixia) for Complex Regional Pain Syndrome
Currently there are no approved treatments for CRPS. Neridronic acid administered by injection is currently being developed to treat CRPS and early results indicate that it has the possibility to control the condition. If approved neridronic acid will be a potential new treatment for CRPS.
Mirogabalin for pain due to fibromyalgia
Mirogabalin is a new drug to treat pain associated with fibromyalgia. Fibromyalgia is a long-term condition that causes pain all over the body. Mirogabalin is taken by mouth once a day at bedtime. If licensed, mirogabalin may offer patients with fibromyalgia an additional treatment option.
XG 102 for post-operative inflammation and pain following cataract surgery
XG 102 is a new drug injected into the eye to treat pain and inflammation in people who have had a cataract operation. A cataract occurs when the lens in the eye becomes cloudy causing blurred vision. Cataracts are very common and usually affect those over the age of 65 years. More than 300,000 cataract …